Genes in panel
STRs in panel
Prev Next
Regions in panel
Prev Next

Genomic newborn screening: BabyScreen+

Gene: ARSA

Green List (high evidence)

ARSA (arylsulfatase A)
EnsemblGeneIds (GRCh38): ENSG00000100299
EnsemblGeneIds (GRCh37): ENSG00000100299
OMIM: 607574, Gene2Phenotype
ARSA is in 19 panels

2 reviews

John Christodoulou (Murdoch Children's Research Institute)

Green List (high evidence)

reatment for metachromatic leukodystrophy

PMID: 25987178
It takes 12 – 24 months after BMT for the disease to stabilise, so if the patient already has clinical disease it will progress during this time.
“Even in asymptomatic patients with the infantile onset type, neurological deterioration and progression of white matter abnormalities on MRI were reported”.


Study by Martin et al 2013 (PMID: 23348427): asymptomatic children with the infantile form stabilise

PMID: 33195324
IV and probably intrathecal ERT doesn’t work

Autologous bone marrow transduced with lentiviral ARSA was effective in a child. The company concerned is registering the therapy with the EMA

So, on balance it looks like treatment (be it BMT or gene therapy delivered to autologous bone marrow) would be of benefit to an asymptomatic child. Therefore, I would suggest we include it the gene.
Created: 19 Oct 2022, 10:59 p.m. | Last Modified: 19 Oct 2022, 10:59 p.m.
Panel Version: 0.588

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

Well established gene-disease association.

Progressive disorder, variable age of onset, including severe infantile forms, which are fatal. However, adult onset also reported.

Treatment: bone marrow transplant.

Clinical trials with intrathecal ARSA, SHP611, among others.
Created: 22 Sep 2022, 1:39 a.m. | Last Modified: 22 Sep 2022, 1:39 a.m.
Panel Version: 0.125

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Metachromatic leukodystrophy, MIM# 250100

History Filter Activity

23 Dec 2022, Gel status: 3

Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag metabolic tag was added to gene: ARSA.

20 Oct 2022, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: ARSA were set to

20 Oct 2022, Gel status: 3

Removed Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review was removed from gene: ARSA.

22 Sep 2022, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: arsa has been classified as Green List (High Evidence).

22 Sep 2022, Gel status: 3

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: ARSA were changed from Metachromatic leukodystrophy to Metachromatic leukodystrophy, MIM# 250100

22 Sep 2022, Gel status: 3

Added Tag, Added Tag, Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review tag was added to gene: ARSA. Tag treatable tag was added to gene: ARSA. Tag clinical trial tag was added to gene: ARSA.

18 Sep 2022, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: ARSA was added gene: ARSA was added to gNBS. Sources: BabySeq Category A gene,Expert Review Green Mode of inheritance for gene: ARSA was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: ARSA were set to Metachromatic leukodystrophy